tradingkey.logo

Mangoceuticals Inc

MGRX
1.800USD
0.000
Close 11/05, 16:00ETQuotes delayed by 15 min
19.16MMarket Cap
LossP/E TTM

Mangoceuticals Inc

1.800
0.000
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Mangoceuticals Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mangoceuticals Inc's Score

Industry at a Glance

Industry Ranking
63 / 78
Overall Ranking
487 / 4616
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mangoceuticals Inc Highlights

StrengthsRisks
Mangoceuticals, Inc. is primarily focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. The Company has developed and is commercially marketing a new brand of erectile dysfunction (ED) products under the brand name Mango and a brand of hair loss products under the brand name Grow. These products are produced at a compounding pharmacy using a proprietary combination of United States Food and Drug Administration (FDA) approved ingredients and are available to patients on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. It is marketing and selling these branded ED and hair loss products exclusively online via its Website at www.MangoRx.com. Its customer platform connects consumers to licensed healthcare professionals through its Website for the provision of care via telehealth. It also owns a global patent portfolio of oral solution.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 6789.73% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 615.87K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 615.87K.
Fairly Valued
The company’s latest PE is -0.62, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 292.25K shares, increasing 33.05% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 31.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 5.65, which is lower than the Healthcare Providers & Services industry's average of 7.24. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 168.11K, representing a year-over-year increase of 3.03%, while its net profit experienced a year-over-year increase of 126.51%.

Score

Industry at a Glance

Previous score
5.65
Change
0

Financials

6.44

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.17

Operational Efficiency

2.57

Growth Potential

5.96

Shareholder Returns

7.11

Mangoceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.50, which is higher than the Healthcare Providers & Services industry's average of 7.09. Its current P/E ratio is -0.62, which is -100.00% below the recent high of 0.00 and -83767.05% above the recent low of -519.98.

Score

Industry at a Glance

Previous score
7.50
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 63/78
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Healthcare Providers & Services industry's average is 7.56.

Score

Industry at a Glance

Previous score
0.00
Change
0

Support & Resistance

No Data
No Data

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 4.01, which is lower than the Healthcare Providers & Services industry's average of 7.02. Sideways: Currently, the stock price is trading between the resistance level at 2.45 and the support level at 1.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
3.83
Change
0.18

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(1)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.146
Sell
RSI(14)
37.318
Neutral
STOCH(KDJ)(9,3,3)
7.901
Oversold
ATR(14)
0.242
High Vlolatility
CCI(14)
-125.273
Sell
Williams %R
94.059
Oversold
TRIX(12,20)
-0.526
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
1.918
Sell
MA10
2.063
Sell
MA20
2.252
Sell
MA50
2.253
Sell
MA100
1.969
Sell
MA200
2.394
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Cohen (Jacob D.)
1.30M
+62.11%
Navy Wharf, Ltd.
1.00M
--
Propre Energie Inc
650.00K
--
Greenfield Investments Ltd
515.00K
--
The Vanguard Group, Inc.
Star Investors
182.61K
--
Johnston (Eugene M)
138.33K
+260.87%
Myers (Kenny)
136.67K
+272.72%
D'Alessio (Lorraine Pamela)
136.67K
+272.72%
Hamilton (Alex P)
126.67K
+375.00%
Isaac (Antonios)
60.00K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 2.05, which is lower than the Healthcare Providers & Services industry's average of 5.44. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.05
Change
0
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+75.36%
240-Day Volatility
+134.08%

Return

Best Daily Return
60 days
+15.00%
120 days
+15.00%
5 years
--
Worst Daily Return
60 days
-13.50%
120 days
-13.50%
5 years
--
Sharpe Ratio
60 days
+0.40
120 days
+0.69
5 years
--

Risk Assessment

Maximum Drawdown
240 days
+75.36%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
-0.30
3 years
--
5 years
--
Skewness
240 days
-0.38
3 years
--
5 years
--

Volatility

Realised Volatility
240 days
+134.08%
5 years
--
Standardised True Range
240 days
+15.78%
5 years
--
Downside Risk-Adjusted Return
120 days
+130.17%
240 days
+130.17%
Maximum Daily Upside Volatility
60 days
+90.49%
Maximum Daily Downside Volatility
60 days
+54.37%

Liquidity

Average Turnover Rate
60 days
+2.23%
120 days
+4.38%
5 years
--
Turnover Deviation
20 days
-99.56%
60 days
-99.57%
120 days
-99.16%

Peer Comparison

Healthcare Providers & Services
Mangoceuticals Inc
Mangoceuticals Inc
MGRX
3.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Natera Inc
Natera Inc
NTRA
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ensign Group Inc
Ensign Group Inc
ENSG
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Encompass Health Corp
Encompass Health Corp
EHC
8.32 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Pediatrix Medical Group Inc
Pediatrix Medical Group Inc
MD
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Option Care Health Inc
Option Care Health Inc
OPCH
8.12 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI